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Results. Ejection fraction was 29+7% (mean&D), the pulmonary capillary wedge pres- 
sure was l&7 mmHg, left ventricular end-diastolic pressure was 22*6 mmHg and mean 
pulmonary artery pressure (mPAP) was 26~6 mmHg. Plasma ET-l levels were similar in 
pulmonary artery (0.931*0.71 fmol/ml) and aorta (0.906*0.6 fmol/ml. p=O.769) and did 
not correlate with mPAP (r-0.139, p&521). Single pass pulmonary ET-l extraction was 
reduced compared with histoncal controls (31*15% vs 47*2%, p<O.OOl), as was plaSma 
clearance of ET-1 (912+610 mllmin YS 1424+77 mllmin, p=O.Ol). Lung clearance 
inversely correlated with mPAP (r=-0.490. p=O.O14). 
Conclusions. Pulmonary ET-l clearance is reduced in relation with the severity of pulmo- 
nary hypertension (PHT) in patients with CHF. While it does not seem to contribute to the 
increase in plasma ET-l levels, this evidence for reduction in endothelial ETB receptor 
activity may contribute to the development of PHT. 
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Victor L. Serebruanv. ChristoDher M. O’Connor. Sinai Center for Thrombosis Research, 
Baltimore, MD, Duke University Medical Center, Durham, NC 
Objectives: We sought to determine whether platelet activity in patients with heart failure 
(HF) is related to an ischemic versus non-ischemic etiology, clinical disease severity or 
adverse clinical outcomes. Background: Platelets activity may affect outcome in patients 
with HF. A prospective evaluation of the relation of baseline platelet function to HF etiol- 
ogy, NYHA class, and clinical outcomes has not been previously reported. Methods: 
Ninety-sir consecutive ambulatory hearl failure outpatients with an EFc .40 and NYHA 
Class II-IV symptoms who presented to the Duke Heart Failure Clinic and fourteen 
healthy controls formed the study groups. Baseline characteristics were determined and 
blood was analyzed for thromboxane (TX) 82, 6-ksto PGFI, platslst contractile force, 
ADPlcollagen shear-induced closure time, whole blood aggregation (WBA) and CD 41, 
CD31, CD62p and CD51/CD61 by flow cytometry. Survival status and hospitalizations 
were determined in the heart failure patient cohort. Results: The median age was 65 
years (22% female, 64% Caucasian). An ischemic etiology was present in 61%. The pop- 
ulation has mild-moderate HF: NYHA class I (l%), II (41%), Ill (46%), and IV (12.5%) and 
severe ventricular dysfunction (median EF = .20). There were 39 clinical events ( 7 
deaths, 3 cardiac transplants, 29 other first hospitalizations) in 305 median days follow- 
up. Platelet activity, indicated by WBA with 5pmol ADP (p=.O4) and TX 82 (p=.Ol), was 
higher in HF patients. WBA was greater than 90” percentile in 22% of HF patients vs 7% 
of controls. Markers of platelet function did not differ between the ischemic and non- 
ischemic groups and was not affected by antecedent aspirin. There was no relation of 
NYHA class or the occurrence of events to platelet activity. Conclusion: Platelet activity 
is heightened in 22% of outpatients with stable heart failure symptoms and is not affected 
by antecedent aspirin therapy. The degree of platelet activation is similar in ischemic and 
non-ischemic HF and is not related to clinical disease severity. Current methods to 
assess platelet activation do not appear to predict outcome. 
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School, Berlin, Gsrmany 
Background: Serum uric acid (UA) could be a valid prognostic marker and useful for 
metabolic, hemodynamic, and functional (MFH) staging in chronic heart failure (CHF). 
Methods: We performed a series of 3 studies. For the initial derivation study, 112 CHF 
patients (age 59*12 y, peak oxygen consumption [VO,] 17f7 mL/kg/min) were recruited. 
We validated the prognostic value of UA in a second, independent study (n=l82). In a 
third study, we investigated the relationship between MFH score and the decission to list 
patients for heart transplantation (rx120). 
Results: In the derivation study (12.month mortality: 24%) the best mortality predicting 
UA cut-off (at 12 months) was 565 pmol/L (independently of age, peak VQ, LVEF, 
diuretic dose, sodium, creatinine, and urea: pcO.0001). In the validation study (12-month 
mortality: 15%). UA _2565ymol/L predicted mortality (hazard ratio 7.14, p<O.OOOl). 
In 16 patients (from both studies) with UA &65 pmol/L, LVEF X25%, and peak VQ >14 
mUkglmin(i.e. with MFH score 3), 12-month survival was lowest (31%), compared to 
patients with 2 (64%). 1 (77%). or no risk factor (98% , p<O.OOOl). Considering all 294 
CHF patients, we found a graded relationship between serum UA and mortality in CHF 
(pcO.0001). Patients with UA in the normal range (a00 ~ol/L) had the best survival (at 
12.months: 93%). compared to patients with UA between 401 and 600 vol/L (87%, RR 
1.76), patients with UA between 601 and 800 pmol/L (54%, RR 6.27), and patients with 
UA >800 wol/L (17%. RR 18.53). 
In an independent study, 51% of patients with MFH score 2 and 89% of patients with 
MFH score 3 were listed for transplantation. The positive predictive value of not being 
listed for heart transplantation with an MFH score O/l was 100%. 
Conclusions: High serum UA levels are a strong and independent marker of impaired 
prognosis in patients with moderate to severe CHF. The relationship between serum UA 
and survival in CHF is graded. MFH staging of CHF patients is feasible 
Royal Oak, MI, University of California, San Diego School of Medicine, Veterans Affairs 
Medical Center, San Diego, CA 
Introduction Recent, approved indications for blood B-type natriuretic peptide (BNP) for 
the diagnosis of congestive heart failure (CHF) and as a prognostic indicator in patients 
with acute coronary syndromes raise questions on how to interpret very high BNP val- 
ues. 
Methods The BNP Multinational Study was a seven-center prospective study of 1586 
patients presenting with acute dyspnea who had blinded BNP levels measured. The ref- 
erence standard for CHF was adjudicated by two independent cardiologists, also blinded 
to BNP results. 
Results A total of 264 subjects (mean age 70.4 years, 57.2% male) had BNP values on 
arrival to the ED of> 1000 pg/ml. Subjects had the following characteristics: prior history 
of CHF 62.1%, history of coronary heart disease 48.5%, hypertension 65.5%, and lung 
disease in 30.3%; physical exam: rales 69.7%, 53 18.9%, elevated jugular venous pres- 
sure 44.3%, hepatic congestion 24.6%, and peripheral edema 66.3%. Abnormal chest x- 
rays wers present in 90.5%. The final diagnoses are shown in the pie chart. Of those with 
pulmonary disease, all subjects had at least one sign of volume overload on physical 
exam. Other diseases in the differential included atrial fibrillation, acute cardiac ishemis.. 
and chronic renal failure. 
Conclusion A BNP level -> 1000 pglml indicates the presence of CHF in 93.2% of 
cases. In 6.8% of cases without CHF, other serious conditions are present suggesting 
cardiac pressure and or volume overload. 
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Neurohumoral Activation in Patients With Chagas’ 
Heart Dlsease 
Victor S. Issa, Amilcar 0. Mocelin, Fernando Bacal, Guilherme V. Guimaraes, Edecio 
Cunha. Giovanni V. Belloni. Jose F. Ramires, Edimar A. Bocchi, Heart Institute (InCor)- 
University of Sao Paula Medical School, Sao Paul& Brazil 
Background. Inflammatory mediators are of paramount importance in heart failure. 
Despite experimental evidence that cytokines play a central role in Chagas’ disease, data 
in humans is scarce. We studied the pattern of inflammatory and neurohumoral response 
in patients with Chagas’ disease as compared to patients with idiopathic dilated cardi- 
omyopathy (IDC). 
Methods. We studied 35 patients with IDC (IDC group) and 28 patients with Chagas’ 
heart disease (CHAGAS group); we measured and compared plasma tumor necrosis 
factor alfa (TNF-a), soluble TNF-a receptor type l(sTNF-RI), soluble Fas (SF@, inter- 
leukin 6 (IL-6), and brain natriuretic peptide (BNP) concentrations in both groups; the 
association between the substances measured and clinical events (heart transplantation 
or death) was ascertained. Patients were stratified according to functional class and peak 
oxygen consumption (VOPmax). 
